Doxazosin
Product Images NDC 67544-273

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 67544-273). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 8mg (67544 273)

Bottle Label 8mg (67544 273)
This is a description of a medication called Doxazosin Mesylate. Each bottle contains 45 tablets with a strength of 8mg. The medication should be stored between 20-25 degrees Celsius and kept away from children. The manufacturing company is Mylan Pharmaceuticals Inc located in Morgantown, WV, and the repackaging company is Aphena Pharmia located in Cookesile, TN 38506. The batch number is 2 and the lot number is N 67544-0273-45.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Structural Formula (A7293678 9b1b 4102 9a79 1000d853dc16 01)

Structural Formula (A7293678 9b1b 4102 9a79 1000d853dc16 01)
FDA Label Image

Figure 1 (A7293678 9b1b 4102 9a79 1000d853dc16 02)

Figure 1 (A7293678 9b1b 4102 9a79 1000d853dc16 02)
FDA Label Image

Table 1 (A7293678 9b1b 4102 9a79 1000d853dc16 03)

Table 1 (A7293678 9b1b 4102 9a79 1000d853dc16 03)
This text is a table presenting data from three different studies evaluating the efficacy of doxazosin in treating benign prostatic hypertrophy (BPH) in combination with hypertension. The studies varied in their duration and dosage regimes. The table reports the maximum flow rate (in mL/sec) and symptom scores in each study for patients receiving either doxazosin or placebo. The table also notes the number of patients in each group and the baseline and mean changes in both parameters. Study 2 presents a graph indicating that the maximum flow rate improved in patients receiving doxazosin compared to placebo. Overall, the text suggests that doxazosin may have a positive effect on BPH symptoms, at least in hypertensive patients.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.